Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasi… (NCT03563326) | Clinical Trial Compass
UnknownPhase 1
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
China40 participantsStarted 2018-08-30
Plain-language summary
To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with EpCAM positive gastric cancer who have peritoneal metastasis at first visit; Patients with highly suspected or previous proven peritoneal metastasis by biopsy, CT, digital rectal examination, etc. who failed to the routine therapies like chemotherapy;
✓. Age between 18 and 75;
✓. Estimated survival time is longer than 3 months;
✓. Eastern Cooperative Oncology Group (ECOG）scores 0-2;
✓. Negative pregnancy test for child-bearing period; both male and female patients should agree to apply effective contraceptive methods in the period of treatment and one year after treatment;
✓. Both patients and families totally understand the objectives and risks of the treatments and sign the informed consent.
Exclusion criteria
✕. Comorbidity with other diseases treated by immunosuppressive drugs or steroids therapy systematically;
✕. Uncontrolled active infection;
✕. HIV positive;
✕. Active hepatic B or C virus infection, active tuberculosis;
✕. Pregnant or lactation female;
✕
What they're measuring
1
EpCAM CAR-T cells treatment related adverse events